A molecule name does not make two products interchangeable. EGRIFTA WR is an FDA-approved finished drug with a defined formulation, manufacturing controls, prescribing information and approved indication. A tesamorelin research material is a separate catalog article intended for laboratory work.
Key takeaways
- Approval applies to a specific finished product and application, not every item named tesamorelin.
- Formulation, excipients, strength, container system and stability data are part of product identity.
- Research material pages should cite clinical evidence as context while refusing therapeutic equivalence claims.
The approved record is formulation-specific
The FDA label describes EGRIFTA WR’s dosage form, vial strength, diluent, storage and product-specific instructions. It also distinguishes EGRIFTA WR from another tesamorelin formulation and states that the formulations are not substitutable. That is a direct demonstration of why active-ingredient name alone is insufficient for equivalence.
Analytical questions for research procurement
Confirm sequence identity, molecular form, purity method, mass confirmation, water and counterion information, and any project-specific impurity or aggregation requirements. Review lot-specific records rather than relying on a web-page specification alone.
If the experiment is intended to reproduce published work, document the differences between the paper’s intervention and the catalog material. Reproducibility begins with describing those differences, not assuming them away.
SEO language that remains scientifically accurate
Use phrases such as “studied as,” “the trial reported” and “the FDA label states” with direct citations. Avoid “works for,” “treats,” “burns fat” or “equivalent to” on a research-material page. Strong SEO can come from completeness and clarity without turning evidence into an unsupported sales claim.
Sources & editorial method
The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.
2 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- EGRIFTA WR (tesamorelin) prescribing informationU.S. Food and Drug Administration. 2025 labeling record for BLA 022505.
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionFalutz J, et al. Journal of Acquired Immune Deficiency Syndromes. PMID 20101189 · DOI 10.1097/QAI.0b013e3181cbdaff
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
